VARDENAFIL HYDROCHLORIDE

Search structure
Trade Names:
Synonyms:
Status: Approved (2003)
Entry Type: Small molecule
Molecule Category: Salt
UNII: IF61NL91H3
Parent Compound: VARDENAFIL

Structure
InChI Key XCMULUAPJXCOHI-UHFFFAOYSA-N
Smile CCCc1nc(C)c2c(O)nc(-c3cc(S(=O)(=O)N4CCN(CC)CC4)ccc3OCC)nn12.Cl
InChI
InChI=1S/C23H32N6O4S.ClH/c1-5-8-20-24-16(4)21-23(30)25-22(26-29(20)21)18-15-17(9-10-19(18)33-7-3)34(31,32)28-13-11-27(6-2)12-14-28;/h9-10,15H,5-8,11-14H2,1-4H3,(H,25,26,30);1H

Physicochemical Descriptors

Property Name Value
Molecular Formula C23H33ClN6O4S
Molecular Weight 525.08
AlogP 2.07
Hydrogen Bond Acceptor 8.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 8.0
Polar Surface Area 112.9
Molecular species NEUTRAL
Aromatic Rings 3.0
Heavy Atoms 34.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Phosphodiesterase 5A inhibitor DailyMed
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Phosphodiesterase Phosphodiesterase 1 Phosphodiesterase 1A
- 180 - - -
Enzyme Phosphodiesterase Phosphodiesterase 1 Phosphodiesterase 1B
- 180 - - -
Enzyme Phosphodiesterase Phosphodiesterase 5 Phosphodiesterase 5A
- 1 - - -

Indications

Mesh Heading Maximum Phase Mesh ID Reference

Related Entries

Scaffolds

Parent

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
31.11
Nervous system disorders
12.04
Vascular disorders
8.07
Injury, poisoning and procedural complications
6.5
Eye disorders
6.12
Skin and subcutaneous tissue disorders
4.66
Psychiatric disorders
4.13
Cardiac disorders
3.99
Reproductive system and breast disorders
3.74
Investigations
3.38
Gastrointestinal disorders
3.35
Respiratory, thoracic and mediastinal disorders
3.13
Product issues
2.82

Cross References

Resources Reference
ChEMBL CHEMBL1339
FDA SRS IF61NL91H3
Guide to Pharmacology 7320
PDB VDN
PubChem 135413545
SureChEMBL SCHEMBL973820
ZINC ZINC18324776
CONTENTS